India, Oct. 13 -- New research from Novo Nordisk A/S (NVO) and Eli Lilly and Company (LLY) suggests that their GLP-1 drugs may slow down certain biological signs of aging by two to four years.
The two drugmakers presented their findings at the 13th annual Aging Research and Drug Discovery (ARDD) conference last weekend.
Novo Nordisk researchers examined existing clinical trial data to understand how semaglutide affects biological markers linked to aging. The study found that people taking semaglutide showed improvements in these markers compared with those who received a placebo. However, the results varied depending on the type of aging clock used and the organs examined.
Notably, most measurements suggested that semaglutide slowed biol...